| Ident. | Authors (with country if any) | Title |
|---|
| 000011 (2021) |
Matthieu Million [France] ; Audrey Giraud-Gatineau [France] ; Jean-Christophe Lagier [France] ; Philippe Parola [France] ; Philippe Gautret [France] ; Didier Raoult [France] | Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin. |
| 000015 (2021) |
Roberto Ariel Abelda O Zu Iga [Mexique] ; Silvia Mercedes Coca [Mexique] ; Giuliana Florencia Abelda O [Mexique] ; Ruth Ana María González-Villoria [Mexique] | Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. |
| 000016 (2021) |
Claudia Lilli ; Annibale Biggeri [Italie] ; Chiara Zingaretti ; Bernadette Vertogen ; Valeria Frassineti ; Roberto Vespignani ; Veruska Grossi ; Caterina Florescu ; Laura Matteucci ; Chiara Pazzi ; Alberto Bongiovanni ; Francesco Limarzi ; Valentina Fausti ; Lucia Bertoni ; Caterina Donati ; Francesca Galardi ; Nicola Gentili ; Francesco Mazza ; Giovanni Martinelli ; Oriana Nanni | Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine. |
| 000027 (2021) |
S. Ortonobes Roig [Espagne] ; N. Soler-Blanco ; I. Torrente Jiménez ; E. Van Den Eynde Otero ; M. Moreno-Ari O ; M. G Mez-Valent | [Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients]. |
| 000028 (2021) |
X S Wang [République populaire de Chine] ; J H Cai [République populaire de Chine] ; M. Zeng [République populaire de Chine] ; H. Tian [République populaire de Chine] ; H L Chang [République populaire de Chine] ; Y L Ge [République populaire de Chine] ; J J Li [République populaire de Chine] ; Z Q Wei [République populaire de Chine] ; J S Wang [République populaire de Chine] | [Clinical analysis of liver chemistries in children and adolescent with 2019-nCoV infection]. |
| 000037 (2021) |
Isabel Fambuena-Muedra [Espagne] ; Marta Jiménez-García [Belgique] ; Sarah Hershko [Belgique] ; Irene Altemir-G Mez [Espagne] ; Ana Tobarra-L Pez [Espagne] | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. |
| 000046 (2021) |
Paulo Roberto Bignardi [Brésil] ; Carolina Santos Vengrus [Brésil] ; Bruno Matos Aquino [Brésil] ; Alcindo Cerci Neto [Brésil] | Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. |
| 000060 (2021) |
Diana Laila Ramatillah [Indonésie] ; Suri Isnaini [Indonésie] | Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. |
| 000084 (2021) |
Bhanu Prasad Venkatesulu [États-Unis] ; Viveksandeep Thoguluva Chandrasekar [États-Unis] ; Prashanth Giridhar [Inde] ; Pragathee V [Inde] ; Harsh K. Patel [États-Unis] ; Jacob Manteuffel [États-Unis] | The mechanistic rationale of drugs, primary endpoints, geographical distribution of clinical trials against severe acute respiratory syndrome-related coronavirus-2: A systematic review. |
| 000095 (2021) |
Po-Liang Chen [République populaire de Chine] ; Yi-Han Hsiao [République populaire de Chine] ; Chien Chuang [République populaire de Chine] ; Jia-Yih Feng [République populaire de Chine] ; Hsiang-Ling Ho [République populaire de Chine] ; Yi-Tsung Lin [République populaire de Chine] ; Su-Jung Chen [République populaire de Chine] ; Shiang-Fen Huang [République populaire de Chine] ; Hsin-Pai Chen [République populaire de Chine] ; Teh-Ying Chou [République populaire de Chine] ; Yuh-Min Chen [République populaire de Chine] ; Fu-Der Wang [République populaire de Chine] | The clinical manifestations and interval changes of reverse-transcriptase quantitative polymerase chain reactions among different specimens of coronavirus disease 2019 patients. |
| 000105 (2021) |
Nour K. Younis [Liban] ; Rana O. Zareef [Liban] ; Mohammad Ali N. Maktabi [Liban] ; Rami Mahfouz [Liban] | The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. |
| 000137 (2021) |
Ça La Begüm Apayd N [Turquie] ; Gözde Ç Nar [Turquie] ; Gökçe Cihan-Üstünda [Turquie] | Small-molecule antiviral agents in ongoing clinical trials for COVID-19. |
| 000155 (2021) |
Alberto Enrico Maraolo [Italie] ; Adriano Grossi [Italie] | Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials. |
| 000160 (2021) |
Saeidreza Jamalimoghadamsiahkali [Iran] ; Besharat Zarezade [Iran] ; Sogol Koolaji [Iran] ; Seyedahmad Seyedalinaghi [Iran] ; Abolfazl Zendehdel [Iran] ; Mohammad Tabarestani [Iran] ; Ehsan Sekhavati Moghadam [Iran] ; Ladan Abbasian [Iran] ; Seyed Ali Dehghan Manshadi [Iran] ; Mohamadreza Salehi [Iran] ; Malihe Hasannezhad [Iran] ; Sara Ghaderkhani [Iran] ; Mohsen Meidani [Iran] ; Faeze Salahshour [Iran] ; Fatemeh Jafari [Iran] ; Navid Manafi [Canada] ; Fereshteh Ghiasvand [Iran] | Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. |
| 000169 (2021) |
Bianca D. Balmant [Brésil] ; Raquel S. Torrinhas [Brésil] ; Ilanna M. Rocha [Brésil] ; Danielle C. Fonseca [Brésil] ; Francisco F C. Formiga [Brésil] ; Eloisa S D O. Bonfá [Brésil] ; Eduardo F. Borba [Brésil] ; Dan L. Waitzberg [Brésil] | SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy-Is there a link? |
| 000190 (2021) |
Dingzhong Li [République populaire de Chine] ; Jianbing Hu [République populaire de Chine] ; Dian Li [République populaire de Chine] ; Weijun Yang [République populaire de Chine] ; Shuang-Feng Yin [République populaire de Chine] ; Renhua Qiu [République populaire de Chine] | Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. |
| 000195 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| 000211 (2021) |
Sebastian E. Sattui [États-Unis] ; Elizabeth R. Graef [États-Unis] ; Jean W. Liew [États-Unis] ; Jeffrey A. Sparks [États-Unis] ; Alfred H J. Kim [États-Unis] | Reply to 'Taking a stand against the politicization of medical research: how "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of science'. |
| 000218 (2021) |
Marcelo Rodrigues Dos Santos [Brésil] | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. |
| 000276 (2021) |
Nida Bokharee [Pakistan] ; Yusra Habib Khan ; Aisha Khokhar [Pakistan] ; Tauqeer Hussain Mallhi ; Nasser Hadal Alotaibi ; Maria Rasheed [Pakistan] | Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. |
| 000279 (2021) |
Osama A. Badary [Égypte] | Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. |
| 000297 (2021) |
Havva Kocayi It [Turquie] ; Kezban Özmen Süner [Turquie] ; Yakup Tomak [Turquie] ; Gürkan Demir [Turquie] ; Selçuk Yaylac [Turquie] ; Hamad Dheir [Turquie] ; Ertu Rul Güçlü [Turquie] ; Ali Fuat Erdem [Turquie] | Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. |
| 000299 (2021) |
Marko Boban [Croatie] | Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. |
| 000301 (2021) |
Kenneth Sands [États-Unis] ; Richard Wenzel [États-Unis] ; Laura Mclean [États-Unis] ; Kimberly Korwek [États-Unis] ; Jonathon Roach [États-Unis] ; Karla Miller [États-Unis] ; Russell E. Poland [États-Unis] ; L Hayley Burgess [États-Unis] ; Edmund Jackson [États-Unis] ; Jonathan B. Perlin [États-Unis] | No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. |
| 000304 (2021) |
Sandra Elizabeth Barbosa Da Silva ; José Arion Da Silva Moura ; Tiago Rafael De Sousa Nunes ; Ivan Da Rocha Pitta ; Marina Galdino Da Rocha Pitta | New Trends On Biological Activities And Clinical Studies Of Quinolinic Analogues: A Review. |
| 000321 (2021) |
Zakariya Kashour [Canada] ; Tarek Kashour ; Danielle Gerberi [États-Unis] ; Imad M. Tleyjeh [Arabie saoudite, États-Unis] | Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. |
| 000338 (2021) |
Florence Rodgers [Royaume-Uni] ; Toby Pepperrell [Royaume-Uni] ; Sarai Keestra [Pays-Bas, Royaume-Uni] ; Victoria Pilkington [Royaume-Uni] | Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs. |
| 000353 (2021) |
Ji-Won Kim [Corée du Sud] ; Eun Jin Kim [Corée du Sud] ; Hyun Hee Kwon [Corée du Sud] ; Chi Young Jung [Corée du Sud] ; Kyung Chan Kim [Corée du Sud] ; Jung-Yoon Choe [Corée du Sud] ; Hyo-Lim Hong [Corée du Sud] | Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. |
| 000356 (2021) |
Mohamed O. Saad [Qatar] | Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". |
| 000373 (2021) |
Irina Panovska-Stavridis ; Nevenka Ridova ; Tatjana Stojanoska ; Ilir Demiri ; Milena Stevanovic ; Simona Stojanovska ; Tara Ristevska ; Aleksandar Dimkovski ; Venko Filipce ; Aleksandar Dimovski ; Aleksandra Grozdanova | Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). |
| 000379 (2021) |
Ivan Guerra [Espagne] ; Alicia Algaba [Espagne] ; Laura Jiménez [Espagne] ; M. Mar Aller [Espagne] ; Daniel Garza [Espagne] ; Daniel Bonillo [Espagne] ; Laura María Molina Esteban [Espagne] ; Fernando Bermejo [Espagne] | Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain. |
| 000384 (2021) |
Bérénice Charrez [États-Unis] ; Verena Charwat [États-Unis] ; Brian Siemons [États-Unis] ; Henrik Finsberg [Norvège] ; Evan W. Miller [États-Unis] ; Andrew G. Edwards [États-Unis] ; Kevin E. Healy [États-Unis] | In vitro safety "clinical trial" of the cardiac liability of drug polytherapy. |
| 000408 (2021) |
Christine Johnston [États-Unis] ; Elizabeth R. Brown [États-Unis] ; Jenell Stewart [États-Unis] ; Helen C Stankiewicz Karita [États-Unis] ; Patricia J. Kissinger [États-Unis] ; John Dwyer [États-Unis] ; Sybil Hosek [États-Unis] ; Temitope Oyedele [États-Unis] ; Michael K. Paasche-Orlow [États-Unis] ; Kristopher Paolino [États-Unis] ; Kate B. Heller [États-Unis] ; Hannah Leingang [États-Unis] ; Harald S. Haugen [États-Unis] ; Tracy Q. Dong [États-Unis] ; Anna Bershteyn [États-Unis] ; Arun R. Sridhar [États-Unis] ; Jeanne Poole [États-Unis] ; Peter A. Noseworthy [États-Unis] ; Michael J. Ackerman [États-Unis] ; Susan Morrison [États-Unis] ; Alexander L. Greninger [États-Unis] ; Meei-Li Huang [États-Unis] ; Keith R. Jerome [États-Unis] ; Mark H. Wener [États-Unis] ; Anna Wald [États-Unis] ; Joshua T. Schiffer [États-Unis] ; Connie Celum [États-Unis] ; Helen Y. Chu [États-Unis] ; Ruanne V. Barnabas [États-Unis] ; Jared M. Baeten [États-Unis] | Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. |
| 000426 (2021) |
Lucie Pothen [Belgique] ; Halil Yildiz [Belgique] ; Mathilde Mbouck Samnick [Royaume-Uni] ; Jean Cyr Yombi [Belgique] | Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice? |
| 000437 (2021) |
Hozaifa Khalil Elsawah [Égypte] ; Mohamed Ahmed Elsokary [Égypte] ; Mahmoud Gamal Elrazzaz [Égypte] ; Ahmed Hanei Elshafie [Égypte] | Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. |
| 000448 (2021) |
Philippe Gautret [France] ; Jean-Christophe Lagier [France] ; Stéphane Honoré [France] ; Van Thuan Hoang [Viêt Nam] ; Philippe Colson [France] ; Didier Raoult [France] | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. |
| 000459 (2021) |
Archana Asundi [États-Unis] ; Jack Resnik [États-Unis] ; Peter A. Benedict [États-Unis] ; Marlena Shin [États-Unis] ; A. Rani Elwy [États-Unis] ; Westyn Branch-Elliman [États-Unis] | How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols. |
| 000460 (2021) |
Alexey Komissarov [Russie] ; Ivan Molodtsov [Russie] ; Oxana Ivanova [Russie] ; Elena Maryukhnich [Russie] ; Svetlana Kudryavtseva [Russie] ; Alexey Mazus [Russie] ; Evgeniy Nikonov [Russie] ; Elena Vasilieva [Russie] | High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration. |
| 000476 (2021) |
Angela Patrì [Italie] ; Maria Vargas [Italie] ; Pasquale Buonanno [Italie] ; Maria Carmela Annunziata [Italie] ; Daniela Russo [Italie] ; Stefania Staibano [Italie] ; Giuseppe Servillo [Italie] ; Gabriella Fabbrocini [Italie] | From SARS-CoV-2 hematogenous spreading to endothelial dysfunction: clinical-histopathological study of cutaneous signs of COVID-19. |
| 000478 (2021) |
Hardeep Kaur [Inde] ; Phulen Sarma [Inde] ; Anusuya Bhattacharyya [Inde] ; Manisha Prajapat [Inde] ; Subodh Kumar [Inde] ; Ajay Prakash [Inde] ; Bikash Medhi [Inde] | Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable? |
| 000479 (2021) |
Carlos Gustavo Wambier [États-Unis] | Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". |
| 000502 (2021) |
Tatiane Bomfim Ribeiro [Brésil] ; Talita Aona Mazotti [Brésil] ; Nayara Aparecida De Oliveira Silva [Brésil] ; Airton Tetelbom Stein [Brésil] ; Fredi Alexander Diaz-Quijano [Brésil] ; Daniela Oliveira De Melo [Brésil] | Evaluation of the initial response in clinical trial efforts for COVID-19 in Brazil. |
| 000511 (2021) |
Rujipas Sirijatuphat [Thaïlande] ; Yupin Suputtamongkol [Thaïlande] ; Nasikarn Angkasekwinai [Thaïlande] ; Navin Horthongkham [Thaïlande] ; Methee Chayakulkeeree [Thaïlande] ; Pinyo Rattanaumpawan [Thaïlande] ; Pornpan Koomanachai [Thaïlande] ; Susan Assanasen [Thaïlande] ; Yong Rongrungruang [Thaïlande] ; Nitipatana Chierakul [Thaïlande] ; Ranistha Ratanarat [Thaïlande] ; Anupop Jitmuang [Thaïlande] ; Walaiporn Wangchinda [Thaïlande] ; Wannee Kantakamalakul [Thaïlande] | Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital. |
| 000524 (2021) |
Amirreza Roostaei Firozabad [Iran] ; Zohreh Akhoundi Meybodi [Iran] ; Seyed Ruhollah Mousavinasab [Iran] ; Adeleh Sahebnasagh [Iran] ; Mohsen Gholinataj Jelodar [Iran] ; Iman Karimzadeh [Iran] ; Solomon Habtemariam [Royaume-Uni] ; Fatemeh Saghafi [Iran] | Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial. |
| 000525 (2021) |
Benjamin S. Abella [États-Unis] ; Eliana L. Jolkovsky [États-Unis] ; Barbara T. Biney [États-Unis] ; Julie E. Uspal [États-Unis] ; Matthew C. Hyman [États-Unis] ; Ian Frank [États-Unis] ; Scott E. Hensley [États-Unis] ; Saar Gill [États-Unis] ; Dan T. Vogl [États-Unis] ; Ivan Maillard [États-Unis] ; Daria V. Babushok [États-Unis] ; Alexander C. Huang [États-Unis] ; Sunita D. Nasta [États-Unis] ; Jennifer C. Walsh [États-Unis] ; E Paul Wiletyo [États-Unis] ; Phyllis A. Gimotty [États-Unis] ; Michael C. Milone [États-Unis] ; Ravi K. Amaravadi [États-Unis] | Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. |
| 000542 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. |
| 000544 (2021) |
Gilmar Reis [Brésil] ; Eduardo Augusto Dos Santos Moreira Silva [Brésil] ; Daniela Carla Medeiros Silva [Brésil] ; Lehana Thabane [Canada] ; Gurmit Singh [Canada] ; Jay J H. Park [Canada] ; Jamie I. Forrest [Canada] ; Ofir Harari [Canada] ; Castilho Vitor Quirino Dos Santos [Brésil] ; Ana Paula Figueiredo Guimarães De Almeida [Brésil] ; Adhemar Dias De Figueiredo Neto [Brésil] ; Leonardo Cançado Monteiro Savassi [Brésil] ; Aline Cruz Milagres [Brésil] ; Mauro Martins Teixeira [Brésil] ; Maria Izabel Campos Simplicio [Brésil] ; Luciene Barra Ribeiro [Brésil] ; Rosemary Oliveira [Brésil] ; Edward J. Mills [Canada] | Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. |
| 000546 (2021) |
Luis Gabriel Parra-Lara [Colombie] ; Juan José Martinez-Arboleda [Colombie] ; Daniel Francisco Isaza-Pierotti [États-Unis] ; Fernando Rosso [Colombie] | Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| 000547 (2021) |
Steven M. Smoke [États-Unis] ; Karan Raja [États-Unis] ; Patrick Hilden [États-Unis] ; Nicole M. Daniel [États-Unis] | Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study. |
| 000548 (2021) |
Andrea Giacomelli [Italie] ; Gabriele Pagani [Italie] ; Anna L. Ridolfo [Italie] ; Letizia Oreni [Italie] ; Federico Conti [Italie] ; Laura Pezzati [Italie] ; Lucia Bradanini [Italie] ; Giacomo Casalini [Italie] ; Cinzia Bassoli [Italie] ; Valentina Morena [Italie] ; Simone Passerini [Italie] ; Giuliano Rizzardini [Italie, Afrique du Sud] ; Chiara Cogliati [Italie] ; Elisa Ceriani [Italie] ; Riccardo Colombo [Italie] ; Stefano Rusconi [Italie] ; Cristina Gervasoni [Italie] ; Dario Cattaneo [Italie] ; Spinello Antinori [Italie] ; Massimo Galli [Italie] | Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. |
| 000552 (2021) |
Sook Wah Yee [États-Unis] ; Bianca Vora [États-Unis] ; Tomiko Oskotsky [États-Unis] ; Ling Zou [États-Unis] ; Sebastian Jakobsen [États-Unis] ; Osatohanmwen J. Enogieru [États-Unis] ; Megan L. Koleske [États-Unis] ; Idit Kosti [États-Unis] ; Mattias Rödin [États-Unis] ; Marina Sirota [États-Unis] ; Kathleen M. Giacomini [États-Unis] | Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. |
